ArticleBMC infectious diseases2024

Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.

Ameena Goga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.